Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
Year: 2010
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Atherosclerosis
Authors: Eric A. Schwartz, Juraj Koska, Michael P. Mullin, Iyad Syoufi, Dawn C. Schwenke, Peter D. Reaven
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2071539395